BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38085293)

  • 1. Recent trends in incidence, survival and treatment of multiple myeloma in Finland - a nationwide cohort study.
    Ruotsalainen J; Lehmus L; Putkonen M; Lievonen J; Kallio A; Raittinen P; Summanen M; Kosunen M; Korhonen MJ
    Ann Hematol; 2024 Apr; 103(4):1273-1284. PubMed ID: 38085293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].
    Ning X; Wei X; Guo X; Wei Q; Huang F; Fan Z; Xu N; Sun J; Feng R; Liu Q; Wei Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(9):1420-1425. PubMed ID: 34658359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and survival trends in Finnish multiple myeloma patients-a nationwide real-world evidence study.
    Toppila I; Miettinen T; Lassenius MI; Lievonen J; Bauer M; Anttila P
    Ann Hematol; 2021 Jul; 100(7):1779-1787. PubMed ID: 33712865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
    Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
    Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
    Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
    Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT; Lonial S; Nooka AK
    Transplant Cell Ther; 2022 Feb; 28(2):75.e1-75.e7. PubMed ID: 34626863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
    Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
    Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
    Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R
    Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.
    Luoma S; Anttila P; Säily M; Lundan T; Heiskanen J; Siitonen T; Kakko S; Putkonen M; Ollikainen H; Terävä V; Sankelo M; Partanen A; Launonen K; Räsänen A; Sikiö A; Suominen M; Bazia P; Kananen K; Lievonen J; Selander T; Pelliniemi TT; Ilveskero S; Huotari V; Mäntymaa P; Tienhaara A; Jantunen E; Silvennoinen R
    Ann Hematol; 2019 Dec; 98(12):2781-2792. PubMed ID: 31673775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
    Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
    Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis.
    Suzuki K; Shimazu Y; Minakata D; Ikeda T; Takahashi H; Tsukada N; Kanda Y; Doki N; Nishiwaki K; Miwa A; Sawa M; Kataoka K; Hiramoto N; Ota S; Itagaki M; Ichinohe T; Atsuta Y; Yano S; Kawamura K;
    Transplant Cell Ther; 2023 Nov; 29(11):688.e1-688.e13. PubMed ID: 37574125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis.
    Tangen JM; Tjønnfjord GE; Gulbrandsen N; Gedde-Dahl T; Stormorken E; Anderson K; Vo CD; Schjesvold FH;
    BMC Cancer; 2018 Aug; 18(1):801. PubMed ID: 30089450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
    Mian H; Reece D; Masih-Khan E; McCurdy A; Kardjadj M; Jimenez-Zepeda VH; Song K; Louzada M; LeBlanc R; Sebag M; White D; Stakiw J; Reiman A; Kotb R; Aslam M; Gul E; Venner CP
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):608-617. PubMed ID: 35379589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.